1711-09-7

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromobenzoyl chloride is used as a synthetic intermediate for the production of various pharmaceutical compounds. It plays a crucial role in the synthesis of 2-(3-bromophenyl)-5-phenyl-1,3,4-oxadiazole and (4-benzhydryl-1,4-diazepan-1-yl)(3-bromophenyl)methanone, which are important molecules in the development of new drugs.
Used in Chemical Synthesis:
3-Bromobenzoyl chloride is also used as a reagent in various chemical reactions, facilitating the formation of new compounds with specific functional groups. Its versatility in chemical synthesis makes it a valuable tool in the development of novel materials and products across different industries.

InChI:InChI=1/C7H4BrClO/c8-6-3-1-2-5(4-6)7(9)10/h1-4H

Upstream product

• 585-76-2 m-bromobenzoic acid 
• 98-88-4 benzoyl chloride 
• 591-18-4 1-Bromo-3-iodobenzene 
• 201230-82-2 carbon monoxide 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 83699-51-8 (3-bromophenyl)-(4-bromophenyl)methanone 
• 109938-90-1 3-bromo-benzoic acid-(1-phenyl-2-pyrrolidino-ethyl ester); hydrochloride 
• 24398-88-7 ethyl 3-bromobenzoate 
• 150698-52-5 2-(3-bromo-benzoylamino)-2-deoxy-D-glucose 
• 6315-88-4 1,4-bis-[4-(3-bromo-benzoyloxy)-benzoyl]-benzene 
• 122315-98-4 3β-(3-bromo-benzoyloxy)-stigmasta-5,22t-diene 
• 7470-29-3 9,9-bis-[4-(3-bromo-benzoyloxy)-phenyl]-10,10-diphenyl-9,10-dihydro-anthracene 

Relevant academic research and scientific papers

A sustainable and simple catalytic system for direct alkynylation of C(sp2)-H bonds with low nickel loadings

A sustainable and simple catalytic system for the atom-economical alkynylation of benzamides with low nickel loadings is described. No organic or metallic oxidants and expensive ligands are required. A broad range of benzamides and bromoalkynes bearing various synthetically useful functional groups are compatible with this reaction. The versatility of this operationally simple protocol has been further demonstrated by the controllable mono- and di-alkynylation. Importantly, substrate/catalyst ratios of up to 200, and a turnover number of 196 were achieved, highlighting the potential of this protocol for synthetic applications.

Rational Design and Synthesis of a Highly Effective Transition State Anolog Inhibitor of the RTEM-1 β-Lactamase

The synthesis of (1R)-1-acetamido-2-(3-carboxyphenyl)ethane boronic acid, a rationally designed transition state anolog competitive inhibitor of the RTEM-1 β-lactamase from Escherichia coli, is reported.Kinetic measurements show that, as designed, it is a

Copper-catalyzed ortho-halogenation of arenes and heteroarenes directed by a removable auxiliary

Copper-catalyzed ortho-halogenation of C(sp2)-H bonds directed by a PIP directing group with NXS (X = Cl, Br, I) has been developed. The reaction is scalable and tolerates a broad range of functional groups and heteroarenes, providing an efficient access to halogenated arenes and heteroarenes.

Effect of a novel compound as dietary supplement on growth of decapod crustaceans

Several conventional methods have been used for many years to accelerate the growth in decapod crustaceans but they are not suitable for aquaculture practices due to their harmful effects on the animals. Concern over water quality, environmental hazards,

Synthesis, Characterization, and Catalytic Studies of Unsymmetrical Chiral NCC Pincer Pd(II) and Ni(II) Complexes Bearing (Imidazolinyl)aryl NHC Ligands

A series of palladium(II) and nickel(II) complexes based on unsymmetrical chiral (imidazolinyl)aryl NHC ligands are reported. The new ligand presursors 3a-g were prepared from commercially available 3-bromobenzoic acid, in which the carboxyl and bromo fun

HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS

The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

Remarkably Efficient Iridium Catalysts for Directed C(sp2)-H and C(sp3)-H Borylation of Diverse Classes of Substrates

Here we describe the discovery of a new class of C-H borylation catalysts and their use for regioselective C-H borylation of aromatic, heteroaromatic, and aliphatic systems. The new catalysts have Ir-C(thienyl) or Ir-C(furyl) anionic ligands instead of the diamine-type neutral chelating ligands used in the standard C-H borylation conditions. It is reported that the employment of these newly discovered catalysts show excellent reactivity and ortho-selectivity for diverse classes of aromatic substrates with high isolated yields. Moreover, the catalysts proved to be efficient for a wide number of aliphatic substrates for selective C(sp3)-H bond borylations. Heterocyclic molecules are selectively borylated using the inherently elevated reactivity of the C-H bonds. A number of late-stage C-H functionalization have been described using the same catalysts. Furthermore, we show that one of the catalysts could be used even in open air for the C(sp2)-H and C(sp3)-H borylations enabling the method more general. Preliminary mechanistic studies suggest that the active catalytic intermediate is the Ir(bis)boryl complex, and the attached ligand acts as bidentate ligand. Collectively, this study underlines the discovery of new class of C-H borylation catalysts that should find wide application in the context of C-H functionalization chemistry.

Palladium-Catalyzed 5-exo-dig Cyclization Cascade, Sequential Amination/Etherification for Stereoselective Construction of 3-Methyleneindolinones

An cascade intramolecular 5-exo-dig cyclization of N-(2-iodophenyl)propiolamides and sequential amination/etherification (with N-hydroxybenzamides, phenyl hydroxycarbamate) protocol for the synthesis of amino- and phenoxy-substituted 3-methyleneindolinones using unexpensive Pd(PPh3)4 as catalyst has been developed. The protocol enables the assembly of structurally important oxindole cores featuring moderate functional group tolerance (particularly the halo group), affording a broad spectrum of products with diverse substituents in good to excellent yields. (Figure presented.).

Structure-Activity Relationship of Phenylpyrazolones against Trypanosoma cruzi

Chagas disease is a neglected parasitic disease caused by the parasitic protozoan Trypanosoma cruzi and currently affects around 8 million people. Previously, 2-isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0227) was discovered to be a sub-micromolar inhibitor (pIC50=6.4) of T. cruzi. So far, SAR investigations of this scaffold have focused on the alkoxy substituent, the pyrazolone nitrogen substituent and the aromatic substituent of the core phenylpyrazolone. In this study, modifications of the phenyldihydropyrazolone scaffold are described. Variations were introduced by installing different substituents on the phenyl core, modifying the geminal dimethyl and installing various bio-isosteres of the dihydropyrazolone group. The anti T. cruzi activity of NPD-0227 could not be surpassed as the most potent compounds show pIC50 values of around 6.3. However, valuable additional SAR data for this interesting scaffold was obtained, and the data suggest that a scaffold hop is feasible as the pyrazolone moiety can be replaced by a oxazole or oxadiazole with minimal loss of activity.

Meta -Substituted benzenesulfonamide: A potent scaffold for the development of metallo-β-lactamase ImiS inhibitors

Metallo-β-lactamase (MβL) ImiS contributes to the emergence of carbapenem resistance. A potent scaffold, meta-substituted benzenesulfonamide, was constructed and assayed against MβLs. The twenty-one obtained molecules specifically inhibited ImiS (IC50 = 0.11-9.3 μM); 2g was found to be the best inhibitor (IC50 = 0.11 μM), and 1g and 2g exhibited partially mixed inhibition with Ki of 8.0 and 0.55 μM. The analysis of the structure-activity relationship revealed that the meta-substitutes improved the inhibitory activity of the inhibitors. Isothermal titration calorimetry (ITC) assays showed that 2g reversibly inhibited ImiS. The benzenesulfonamides exhibited synergistic antibacterial effects against E. coli BL21 (DE3) cells with ImiS, resulting in a 2-4-fold reduction in the MIC of imipenem and meropenem. Also, mouse experiments showed that 2g had synergistic efficacy with meropenem and significantly reduced the bacterial load in the spleen and liver after a single intraperitoneal dose. Tracing the ImiS in living E. coli cells by RS at a super-resolution level (3D-SIM) showed that the target was initially associated on the surface of the cells, then there was a high density of uniform localization distributed in the cytosol of cells, and it finally accumulated in the formation of inclusion bodies at the cell poles. Docking studies suggested that the sulfonamide group acted as a zinc-binding group to coordinate with Zn(ii) and the residual amino acid within the CphA active center, tightly anchoring the inhibitor at the active site. This study provides a highly promising scaffold for the development of inhibitors of ImiS, even the B2 subclasses of MβLs.